UCB to focus on core business in India
UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million
In line with its strategic focus, UCB announces it has entered an agreement with Dr. Reddy’s to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders. The amount of the transaction amounts to INR 8000 million (~ €118 million). The agreement includes the transfer of ~350 members of staff to Dr. Reddy’s. The revenues of the acquired business is ~ INR 1500 million for calendar year 2014.
The agreement is in line with UCB’s strategy to provide the best value for patients and to focus on bringing them innovative drugs while ensuring its mature brands portfolio continues to reach as many people as possible.
Mark McDade, UCB’s Chief Operating Officer said: "UCB is in a strong position with a solid platform for continuous growth thanks to our core products and our promising pipeline. This position allows us to focus on our neurology portfolio in India, providing innovative solutions to patients living with severe diseases. He also explains “Finding the right company for our established brands and our team in India was crucial, and Dr. Reddy’s knowledge of the local market combined with their ambitious plans and excellent reputation convinced us they were the right choice to drive this business forward.”
This agreement does not impact UCB’s 2015 financial guidance.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
